Atavistik Bio closed a $120 million Series B to advance a pipeline of small molecules targeting bleeding disorders and hematologic malignancies. The Cambridge, Massachusetts‑based biotech will use the proceeds to progress lead programs and expand preclinical and translational work. The financing underscores investor interest in differentiated small‑molecule approaches for hematology, a field long dominated by biologics and gene therapies. Atavistik’s capital raise positions it to push candidates into later preclinical stages and into IND‑enabling studies where appropriate.